series-c-plus
Stage
2020
Founded
2
Investors
About
Cimeio Therapeutics develops a novel immunotherapy platform that pairs cell-shielding technology with precisely targeted immunotherapies, aiming to improve outcomes for patients with hematologic malignancies and autoimmune diseases.
Explore Cimeio Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.